BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its first quarter 2026 financial results on May 7, 2026, followed by a conference call and live webcast at 4:30pm ET. Management will provide an overview of financial results and a general business update.

BioLife Solutions received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system designed for frozen biologic materials in cell and gene therapy manufacturing. The product addresses documented container failures in CGT manufacturing where flexible cryobags have been susceptible to stress fractures and seal fatigue. CryoCase was launched in 2025 and is part of BioLife's CellSeal portfolio.

BioLife Solutions reported strong 2025 results with 29% full-year revenue growth to $96.2 million and Q4 revenue of $24.8 million (up 20% YoY). The company achieved GAAP net income of $2.1 million in Q4 and adjusted EBITDA of $6.9 million (28% margin). For 2026, BioLife projects revenue growth of 17-20% to $112.5-115 million and expects full-year GAAP profitability. The company completed the strategic divestiture of evo subsidiary in October 2025 for $25.5 million, positioning itself as a focused cell processing company.

BioLife Solutions (NASDAQ: BLFS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, followed by a conference call and webcast at 4:30pm ET. Management will provide an overview of financial results and a general business update.

BioLife Solutions (NASDAQ: BLFS) has entered into a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for the cell and gene therapy market. The agreement grants BioLife exclusive worldwide distribution rights to specific Qkine products and includes collaboration on product development using BioLife's CellSeal® Connect vial system. The global cytokines market is estimated at $500 million annually and projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030.

The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.

BioLife Solutions reported Q4 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year, and full-year 2025 revenue of $96.2 million, exceeding guidance and representing 29% growth. The company, now positioned as a pure-play cell processing company following the divestiture of its evo product line, expects continued revenue growth and EBITDA margin expansion in 2026.

BioLife Solutions' CFO Troy Wichterman sold 30,000 shares for $771,600, representing 16.4% of his direct holdings. The company reported Q3 revenue growth of 31.2%, but the stock has underperformed market indexes over the past year.

The global cell therapy packaging market is projected to grow from $419.57 million in 2025 to $1.27 billion by 2034, driven by increasing demand for cell and gene therapies, technological advancements, and specialized packaging solutions.

The cell and gene therapy infrastructure market is projected to experience significant revenue growth from 2025 to 2034, driven by increasing demand for advanced therapeutic development, manufacturing capacity expansion, and technological advancements.

BioLife Solutions announced its management will participate in multiple investor conferences in November and December 2025, including events in Napa Valley, Nashville, London, and virtual conferences focused on small-cap and healthcare sectors.

BioLife Solutions will release its Q3 2025 financial results on November 6, 2025, with a conference call and webcast scheduled for 4:30pm ET to discuss financial performance and business updates.